ClinicalTrials.gg
Active, not recruitingNCT05451810Updated Sep 11, 2026

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

A Phase 2 interventional study of Epcoritamab in Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma, sponsored by Genmab. Active, not recruiting at 72 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Genmab · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
4th of 24
184 · median 41
Started
2022
with 2 others
Phase 2
14 of 24
12 open now
Primary completion
2027-03
later than 3 of 22 live
Registered
5th of 24
by date
Lead sponsor
8 of 24
Genmab

Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by planned enrollment, is one of 3 that started in 2022, is one of 14 in phase 2, reaches primary completion later than 3 of the 22 other live ones, and was the 5th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About epcoritamab

epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) who have received at least 1 prior line of systemic antilymphoma therapy including at least 1 anti-CD20 monoclonal antibody-containing therapy or R/R classic follicular lymphoma (cFL). Adverse events will be assessed.

Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R cFL. Study doctors will assess participants in a monotherapy treatment arm of epcoritamab. Participants will receive escalating doses of epcoritamab, until full dose is achieved. Approximately 184 adult participants with R/R DLBCL and R/R cFL will be enrolled in the study in approximately 80 sites in the United States of America.

Participants will receive escalating doses of subcutaneous epcoritamab, until full dose is achieved, in 28-day cycles.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
  • Classic Follicular Lymphoma

Keywords

  • Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Relapsed or Refractory Classic Follicular Lymphoma
  • Non-Hodgkins Lymphoma
  • Cancer
  • Epcoritamab
  • ABBV-GMAB-3013
  • EPCORE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >3 months on standard of care (SOC) treatment.
  • Meets the following disease activity criteria:

    -- (R/R) Diffuse Large B-Cell Lymphoma (DLBCL):

    • Documented CD20+ mature B-cell neoplasm according to the the 5th edition of World Health Organization (WHO) classification of Haematolymphoid Tumours, based on most recent representative pathology report;
    • Diffuse large B-cell lymphoma, not otherwise specified (NOS) (de novo or transformed from follicular lymphoma (FL) or Marginal Zone Lymphoma [MZL]);
    • High-grade B-cell Lymphoma including "double-hit" or "triple-hit" DLBCL (technically classified in WHO 2022 or 2016 as high-grade B-cell lymphoma [HGBCL], with MYC and BCL2 and/or BCL6 translocations).
    • Follicular large B-cell lymphoma (FLBL, formerly FL grade 3B);
    • Relapsed or refractory disease and previously treated with at least 1 prior systemic antineoplastic therapies including at least 1 anti-CD20 monoclonal antibody-containing therapy; Note: Relapsed disease is defined as disease that previously responded to therapy but progressed >= 6 months after completion of therapy. Refractory disease is defined as disease that either progressed during therapy, failed to achieve an objective response to prior therapy, or progressed within 6 months after completion of therapy (including maintenance therapy).
    • Either failed prior hematopoietic stem cell transplantation (HSCT), or ineligible for autologous HSCT including but not limited to age, (ECOG) performance status, participant decision, comorbidities and/or insufficient response to prior treatment.
  • R/R Follicular Lymphoma:

    • Documented CD20+ mature B-cell neoplasm according to the 5th edition of WHO classification of Haematolymphoid Tumours, based on representative pathology report;

      --- Classic FL (cFL) (previously FL grade 1, 2, or 3a) without clinical or pathological evidence of transformation;

    • Relapsed or refractory disease and previously treated with at least 2 prior lines of systemic antineoplastic therapies including at least 1 anti-CD20 monoclonal antibody containing therapy; Note: Relapsed disease is defined as disease that previously responded to therapy but progressed >= 6 months after completion of therapy. Refractory disease is defined as disease that either progressed during therapy, failed to achieve an objective response to prior therapy, or progressed within 6 months after completion of therapy (including maintenance therapy).
    • Previously treated with an alkylating agent or lenalidomide;
    • Relapsed or refractory to the last prior line therapy. Previous lymphoma therapy is defined as 1 of the following: At least 2 months of single-agent therapy, at least 2 consecutive cycles of combination therapy, autologous HSCT, immunomodulatory therapy, or radioimmunotherapy.
  • Has at least one target lesion defined as:

    • >= 1 measurable nodal lesion (long axis > 1.5 cm) and/or >= 1 measurable extranodal lesion (long axis > 1.0 cm) on CT (or MRI) AND
    • FDG PET scan demonstrating positive lesion(s) compatible with CT (or MRI) defined anatomical tumor sites.
  • Must have ECOG performance status 0 - 2.
  • Must have acceptable organ (renal, liver, and hematologic) function within the screening period prior to the first dose of study drug:

    • (ANC) >= 1.0 × 10\^9/L (growth factor support allowed in case of bone marrow involvement, but participant must have not received growth factor within 14 days prior to screening lab collection);
    • >= 8.0 g/dL (RBC transfusions permitted, but participants must not have received blood transfusions within 7 days prior to Screening lab collection);
    • count >= 75 × 10\^9/L, or >= 50 × 10\^9/L in the presence of bone marrow involvement or splenomegaly (platelet transfusions are permitted, but participants must not have received blood transfusions within 7 days prior to Screening lab collection);
    • (INR) (or Prothrombin Time [PT]) and aPTT \<= 1.5 × (ULN), unless receiving anticoagulation
    • Serum (AST) and serum alanine aminotransferase (ALT) \<= 3.0 × upper limit of normal (ULN); unless due to hepatic involvement of disease or non-hepatic origin. For participants with hepatic involvement of disease, serum AST and serum ALT \<= 5.0 × ULN
    • Direct \<= 2 × ULN;
    • Estimated creatine clearance () as calculated by Cockcroft-Gault Formula >= 45 mL/min, or estimated (eGFR) as calculated by Modification of Diet in Renal Disease [MDRD] equation >= 45 mL/min;
    • Lymphocyte count \< 5 × 10\^9/L.

Exclusion criteria

Exclusion Criteria:

  • Have a primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma including , at screening as confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan (brain) and, if clinically indicated, by lumbar puncture.
  • Uncontrolled (HIV) infection. HIV viral load that is undetectable and controlled with medication for at least 1 year prior to enrollment is allowed. Note: If participant has no history of HIV infection, HIV testing does not need to be conducted at screening unless it is required per local guidelines or institutional standards.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Main Cohort: Epcoritamab Diffuse Large B-Cell Lymphoma (DLBCL)

    Participants with relapsed or refractory (R/R) DLBCL will receive subcutaneous (SC) epcoritamab in 28 day cycles.

    Drug: Epcoritamab

  • Experimental
    Main Cohort: Epcoritamab Classic Follicular Lymphoma (cFL)

    Participants with R/R cFL will receive SC epcoritamab in 28 day cycles.

    Drug: Epcoritamab

  • Experimental
    Diversity Enriched Cohort: Epcoritamab DLBCL

    Participants with R/R DLBCL will receive SC epcoritamab in 28 day cycles.

    Drug: Epcoritamab

  • Experimental
    Diversity Enriched Cohort: Epcoritamab cFL

    Participants with R/R cFL will receive SC epcoritamab in 28 day cycles.

    Drug: Epcoritamab

Interventions

  • Subcutaneous Injection (SC)

    Also known as: ABBV-GMAB-3013

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Grade 3 or Higher Cytokine Release Syndrome (CRS) Events

    Cytokine Release Syndrome events will be graded using American Society for Transplantation and Cellular Therapy (ASTCT), with a higher grade indicating higher severity.

    Time frame: Up to 3 Months

  2. Percentage of Participants Experiencing Grade 3 or Higher Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events

    ICANS events will be graded using ASTCT, with a higher grade indicating higher severity.

    Time frame: Up to 3 Months

  3. Percentage of Participants Experiencing Grade 3 or Higher Neurotoxicity (Ntox) Events

    Ntox is defined as the percentage of participants who developed at least 1 Grade 3 or higher Ntox since the initiation of epcoritamab treatment.

    Time frame: Up to 3 Months

Secondary outcomes

  1. Best Overall Response (BOR) Determined by Lugano 2014 Criteria Per Investigator Assessment

    BOR is defined as the percentage of participants who achieved best overall response of complete response (CR) or partial response (PR) determined by Lugano 2014 criteria as assessed by investigators.

    Time frame: Up to 3 Months

  2. CR Determined by Lugano 2014 Criteria Per Investigator Assessment

    Complete response is defined as the percentage of participants who achieved best overall response of CR determined by Lugano 2014 criteria as assessed by investigator.

    Time frame: Up to 3 Months

  3. Diversity Enriched Cohort: Incidence of Treatment-Emergent Adverse Events (TEAEs) by Severity Level

    Treatment-emergent events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.

    Time frame: Up to 3 Months

  4. Diversity Enriched Cohort: Severity of TEAEs by Severity Level

    Treatment-emergent events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.

    Time frame: Up to 3 Months

  5. Diversity Enriched Cohort: Incidence of Serious Adverse Events (SAEs) by Severity Level

    A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: Up to 3 Months

  6. Diversity Enriched Cohort: Severity of SAEs by Severity Level

    A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: Up to 3 Months

  7. Diversity Enriched Cohort: Median Time to Onset of CRS of Grade 3 or Higher

    Median time to onset of CRS of Grade 3 or higher.

    Time frame: Up to 3 Months

  8. Diversity Enriched Cohort: Median Time to Resolution of CRS of Grade 3 or Higher

    Median time to resolution of CRS of Grade 3 or higher.

    Time frame: Up to 3 Months

  9. Diversity Enriched Cohort: Median Time to Onset of ICANS of Grade 3 or Higher

    Median time to onset of ICANS of Grade 3 or higher.

    Time frame: Up to 3 Months

  10. Diversity Enriched Cohort: Median Time to Resolution of ICANS of Grade 3 or Higher

    Median time to resolution of ICANS of Grade 3 or higher.

    Time frame: Up to 3 Months

  11. Diversity Enriched Cohort: Median Time to Onset of Ntox of Grade 3 or Higher

    Median time to onset of Ntox of Grade 3 or higher.

    Time frame: Up to 3 Months

  12. Diversity Enriched Cohort: Median Time to Resolution of Ntox of Grade 3 or Higher

    Median time to resolution of Ntox of Grade 3 or higher.

    Time frame: Up to 3 Months

  13. Diversity Enriched Cohort: Percentage of Participants Experiencing Any Adverse Events (AE)s

    An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 3 Months

  14. Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of CRS After the First Full Dose of Epcoritamab

    Percentage of participants receiving various interventions for the management of CRS after the first full dose of epcoritamab.

    Time frame: Up to 3 Months

  15. Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of ICANS After the First Full Dose of Epcoritamab

    Percentage of participants receiving various interventions for the management of ICANS after the first full dose of epcoritamab.

    Time frame: Up to 3 Months

  16. Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of Ntox After the First Full Dose of Epcoritamab

    Percentage of participants receiving various interventions for the management of Ntox after the first full dose of epcoritamab.

    Time frame: Up to 3 Months

  17. Diversity Enriched Cohort: Duration of response (DOR)

    Duration of response is defined for participants who achieved BOR of CR or PR ('responders'), as the time in months from initial CR/PR to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

    Time frame: Up to 3 Months

  18. Diversity Enriched Cohort: Progression-free survival (PFS)

    Progression-free survival is defined as the time in months from the first dose of study drug to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

    Time frame: Up to 3 Months

  19. Diversity Enriched Cohort: Overall survival (OS)

    Overall survival is defined for as the time in months from first dose of epcoritamab to death from any cause.

    Time frame: Up to 3 Months

  20. Diversity Enriched Cohort: Time-to-response (TTR)

    Time to response is defined for participants who achieved BOR of CR or PR ('responders') determined by Lugano 2014 criteria as assessed by investigator, as the time in months from first dose of study drug to initial CR/PR.

    Time frame: Up to 3 Months

  21. Diversity Enriched Cohort: Duration of CR (DOCR)

    The duration of complete response is defined for participants who achieved BOR of CR (Complete Responders), as the duration from the first CR response to the earliest date of disease progression determined per Lugano 2014 criteria, as assessed by the investigator, or death, whichever occurs first.

    Time frame: Up to 3 Months

  22. Diversity Enriched Cohort: Time to Next Treatment

    Time to next treatment is defined as the time from the date of the first dose of study drug to the start of new non-protocol-specified treatment or death from any cause.

    Time frame: Up to 3 Months

07

Study locations

72 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Mar 2027, 55 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's planned 55 months is above that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2022
First posted
Jul 11, 2022
StartActual
Aug 17, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05451810
Lead sponsor
Genmab
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Aug 17, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epcoritamab

Start the discussion